

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 December 2005 (29.12.2005)

PCT

(10) International Publication Number
WO 2005/123092 A1

(51) International Patent Classification⁷: **A61K 31/573**,
31/59, 31/592, 31/593, 47/08, 47/10, 47/14, 47/24, A61P
17/06

(74) Agent: L'OREAL; ANDRAL, Christophe - D.I.P.I., 25-29,
Quai Aulagnier, F-92600 Asnières (FR).

(21) International Application Number:
PCT/EP2005/007974

(22) International Filing Date: 15 June 2005 (15.06.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0406610 17 June 2004 (17.06.2004) FR
10/951,887 29 September 2004 (29.09.2004) US

(71) Applicant (for all designated States except US): GAL-
DERMA S.A. [CH/CH]; Zugerstrasse 8, CH-6330 Cham
(CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ZANUTTO, Leslie
[FR/FR]; 2, Place des Rivaux, F-43230 Paulhaguet (FR).
ORSONI, Sandrine [FR/FR]; Les Jardins de Mandelieu,
522, rue de Boeri, F-06210 Mandelieu (FR). TONGLET,
Emilie [FR/FR]; Les Bastides Chez M. Cambournet, 815,
chemin de la Gabelle, F-06220 Golfe Juan (FR). MAL-
LARD, Claire [FR/FR]; Domaine La Jouvencelle, 1122,
chemins du Château, F-06250 Mougins (FR).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 2005/123092 A1

Compound A + B
↑ ↑
vit D. corticosteroid.
⇒ in a. ≠ to.
Nouveauté

(54) Title: COMPOSITION FOR THE TREATMENT OF PSORIASIS COMPRISING A SILICONE AGENT, A CORTICOS-
TEROID AND VITAMIN D OR A DERIVATIVE THEREOF

(57) Abstract: The present invention relates to a stable anhydrous pharmaceutical composition comprising a silicone agent com-
prising at least one organopolysiloxane elastomer and as active principles vitamin D or a vitamin D derivative and a corticosteroid,
to the process for preparing it and to its use for the topical treatment of psoriasis and other skin disorders.

COMPOSITION FOR THE TREATMENT OF PSORIASIS COMPRISING A SILICONE AGENT, A
CORTICOSTEROID AND VITAMIN D OR A DERIVATIVE THEREOF

The present invention pertains to the field
5 of the formulation of active principles for the purpose
of topical pharmaceutical application.

The present invention relates more
particularly to a stable anhydrous pharmaceutical
composition comprising a silicone agent and as active
10 principles vitamin D or a vitamin D derivative and a
corticosteroid, to the process for preparing it and to
its use for the topical treatment of psoriasis and
other skin disorders.

Vitamin D and its derivatives are generally
15 used in dermatology in the treatment of psoriasis since
they limit the excessive production of cutaneous cells
on the surfaces affected and possess proven advantages
for the treatment of this ailment, which is
characterized in particular by the presence of thick,
20 squamous and dry lesions.

It is known that a certain number of active
principles which exhibit advantageous therapeutic
activity are sensitive to oxidation and in particular
undergo chemical degradation leading to a substantial
25 loss in their activity in the presence of water.

The combination in a single pharmaceutical
composition of vitamin D or a vitamin D derivative with

a corticosteroid is not without its problems. This is because vitamin D or some vitamin D derivatives are unstable in an acidic environment (they have maximum stability at pH values of approximately 8) and certain
5 corticosteroids are unstable in a basic environment (they exhibit maximum stability at a pH of approximately 4 to 6).

Consequently it is appropriate to formulate these active principles in anhydrous compositions.

10 The anhydrous compositions presently available on the market which allow the formulation of water-sensitive active principles while ensuring their effective chemical stability are generally ointment compositions. These ointment compositions are composed
15 principally of petroleum jelly, mineral oil and/or vegetable oil. Some of the compositions comprising petroleum jelly, however, are felt after application to be sticky and greasy, and in addition are shiny. The greasy residue left on the skin prevents the patient
20 afflicted by psoriasis from putting on his or her clothes again after treatment without the risk of leaving greasy marks thereon, which does not necessarily encourage the patient to follow his or her treatment. Non-compliance with the prescribed treatment
25 is one of the main causes of failure; the article "Patients with psoriasis and their compliance with medication, Richards et al., J. Am. Acad. Dermatol.,

Oct. 1999, pp. 581-583" indicates that almost 40% of patients with a chronic disease such as psoriasis do not follow their treatment. The characteristics of the vehicle used in the pharmaceutical compositions are
5 directly linked to the adherence by the patient to his or her treatment.

The ointment compositions presently on the market do not always lend themselves to the formulation of the active principle in a solubilized form.

10 EP 0 255 369 and US 6 103 250 describe formulations based for the most part on silicone derivatives, in which the water-sensitive active substances are formulated in a dispersed form. The dispersed form, however, is generally detrimental to
15 optimum skin penetration and/or release of these active substances.

One of the aims of the present invention is to provide an anhydrous pharmaceutical composition intended for topical application that allows the
20 abovementioned drawbacks to be removed.

Another aim of the present invention is to provide an anhydrous pharmaceutical composition intended for topical application wherein the active principles are in a solubilized form and exhibit
25 prolonged stability.

The present invention accordingly provides an anhydrous pharmaceutical composition intended for the

treatment of psoriasis, characterized in that it comprises a silicone agent comprising at least one organopolysiloxane elastomer and, as active principles, a compound A selected from vitamin D or a vitamin D
5 derivative and a compound B selected from a corticosteroid, the said compounds A and B each being in a solubilized form in the said composition.

By solubilized form is meant a dispersion in the molecular state in a liquid, no crystallization of
10 the active being visible to the naked eye or even under an optical microscope with crossed polarization.

The composition of the invention is intended more particularly for topical application.

The active principles are in the solubilized
15 state, thereby giving the compositions of the invention effective properties of release/skin penetration of each of the said active principles, in conjunction with more advantageous kinetics. The term "effective release/penetration capacity" refers to the effective
20 distribution of the composition of the invention and hence of the active principles it comprises across the stratum corneum of the skin and also across the subcutaneous layers such as the epidermis and the dermis.

25 In particular the pharmaceutical composition according to the present invention is such that the difference in optimum pH stability of the compound A

and the optimum pH stability of the compound B is at least 1.

The term "anhydrous composition" refers for the purposes of the present invention to a composition which is substantially free of water, which is to say that it has a water content of less than or equal to 5% by weight relative to the total weight of the composition, in particular less than or equal to 3%, and especially zero.

10 The active principles forming part of the compositions of the invention, namely vitamin D or a vitamin D derivative and a corticosteroid, possess a therapeutic activity against dermatological ailments or skin complaints such as, for example, psoriasis.

15 By vitamin D is meant the various forms of vitamin D such as, for example, vitamin D₁, D₂, D₃ or vitamin D₄.

By vitamin D derivatives are meant compounds which exhibit biological properties analogous to those of vitamin D, especially properties of transactivation of vitamin D response elements (VDREs), such as an agonist or antagonist activity with regard to receptors of vitamin D or its derivatives. These compounds are not generally natural metabolites of vitamin D. The compounds in question are, in particular, synthetic compounds comprising the vitamin D skeleton with modifications on the side chains and/or likewise

comprising modifications within the skeleton itself. Vitamin D derivatives useful according to the invention thus comprise structural analogues: biaromatics, for example.

5 By way of illustration of vitamin D derivatives mention may be made in particular of calcipotriol, calcitriol or 1,25-dihydroxyvitamin D₃, doxercalciferol, secalcitol, maxacalcitol, seocalcitol, tacalcitol, paricalcitol, falecalcitriol, 1 α ,24S-
10 dihydroxyvitamin D₂, 1(S),3(R)-dihydroxy-20(R)-[((3-(2-hydroxy-2-propyl)phenyl)methoxy)methyl]-9,10-secopregna-5(Z),7(E),10(19)-triene and mixtures thereof.

According to one preferred embodiment of the
15 invention the vitamin D derivative is calcitriol.

As vitamin D derivatives which can be used according to the invention mention may also be made of the derivatives described in WO 02/34235, WO 00/64450, EP1124779, EP1235824, EP1235777, WO 02/94754,
20 WO 03/050067 and WO 00/26167. The compounds described in WO 00/26167 concern structural analogues of vitamin D which exhibit selective activity on proliferation and on cell differentiation without exhibiting any hypercalcemic character.

25 Advantageously the amount of vitamin D or vitamin D derivative in solubilized form in the composition of the invention is from 0.00001 to 5% by

weight relative to the total weight of the composition, preferably from 0.0001 to 3% by weight and more particularly from 0.0003 to 1% by weight.

By corticosteroid is meant for the purposes
5 of the present invention a topical steroid from group I, II, III or IV (strong and weak).

According to one advantageous embodiment of the invention the corticosteroid is selected from the group consisting of betamethasone, clobetasol,
10 clobetasone, desoxymethasone, diflucortolone, diflorasone, fluocinonide, flumethasone, fluocinolone, fluticasone, fluprednidene, halcinonide, hydrocortisone, momethasone, triamcinolone and their pharmaceutically acceptable esters and acetonides and
15 mixtures thereof.

As examples of esters or acetonides mention may be made of those selected from the group consisting of the 17-valerate, 17-propionate, 17,21-dipropionate, acetonide, acetonide-21-N-benzoyl-2-methyl- β -alaninate,
20 acetonide-21-(3,3-dimethylbutyrate) and 17-butyrate.

According to one preferred embodiment of the invention the corticosteroid is clobetasol 17-propionate.

Advantageously the amount of corticosteroid
25 in solubilized form in the composition of the invention is from 0.00005 to 3% by weight relative to the total weight of the composition, preferably from 0.0001 to 1%

by weight, and more particularly from 0.001 to 0.1% by weight.

According to one advantageous embodiment of the invention the active principles are solubilized in the same solvent or in two or more solvents.

The solvent of the present invention is selected from pharmaceutically acceptable compounds, which is to say compounds whose use is compatible in particular with application to the skin, the mucosae and/or the keratin fibres. The solvent is generally fluid, and in particular liquid, at ambient temperature and atmospheric pressure.

As solvents according to the invention mention may be made in particular of the following:

- 15 - linear or branched aliphatic alcohols having 1 to 6 carbon atoms such as ethanol, isopropanol, butanol and mixtures thereof; preferably the solvent is ethanol;
- oils such as caprylic and capric
- 20 triglycerides (Miglyol 812), cetearyl isononanoate (Cetiol SN), vegetable oils such as sweet almond oil, sesame oil, wheatgerm oil, olive oil and mixtures thereof;
- and mixtures thereof.

25 As a suitable solvent in the compositions of the invention mention may also be made of:

- compounds of general formula

$R^3(OCH_2C(R^1)H)_xOR^2$, in which x is an integer ranging from 2 to 60, R^1 in each of the x units is independently H or CH_3 , R^2 is a linear or branched C_{1-20} alkyl or a benzoyl radical and R^3 is H or a phenylcarbonyloxy radical,

- 5 - C_{4-8} dicarboxylic acid di(linear or branched C_{4-10} alkyl) esters, and
- linear or branched C_{12-18} alkyl benzoates.

 It will be appreciated that the selection of the solvent depends in particular on the active

10 principle to be solubilized. According to one preferred embodiment of the invention, when the active principles are calcitriol and clobetasol 17-propionate, the solvent is more particularly absolute ethanol.

 The solvent is generally present in the

15 compositions of the invention in an amount which is on the one hand sufficient to provide the required solubility of the active principles to be formulated and which on the other hand is compatible with the need to preserve prolonged chemical stability of these

20 active principles. In other words the solvent must be chemically inert towards the active principles.

 Advantageously the amount of solvent in a composition of the invention is from 1 to 50% by weight relative to the total weight of the composition,

25 preferably from 2 to 40% by weight and more particularly from 5 to 20% by weight.

 The solvent likewise confers a beneficial

effect on the skin penetration rate of the active principles.

Moreover the solvent may also be useful for promoting the compatibility of the silicone agent with one or more other components present in the composition.

According to the invention, one or more cosolvents may be added to the composition. The following non-comprehensive list describes examples of cosolvents which may potentially be used according to the invention:

Commercial name	Chemical name
PROPYLENE GLYCOL	PROPANE-DIOL 1,2
TRANSCUTOL HP	DIETHYLENE GLYCOL MONOETHYL ETHER
PEG 400	MACROGOL 400
PHARMASOLVE	N METHYL 2 PYRROLIDONE
TWEEN 80	POLYSORBATE 80
AUSTRALIAN TEA TREE OIL	MELALEUCA ALTERNIFOLIA
PLUROL DIISOTEARIQUE	TRIGLYCEROL DIISOSTEARATE
BENZYL ALCOHOL	BENZYLIC ALCOHOL
PHENOXYETHANOL	PHENOXYETHANOL
ISOPROPANOL	PROPANOL-2
CRODAMOL DA	DIISOPROPYL ADIPATE
EUTANOL V-PH	OLEYL ALCOHOL

HEXYLENE GLYCOL	METHYL-2-PENTANEDIOL-1,2
PHENYL ETHYL ALCOHOL	2-PHENYLETHANOL
HYDROLITE-5	PENTYLENE GLYCOL
ARLASOLVE DMI	DIMETHYL ISOSORBIDE
SOLUTOL HS-15	MACROGOL-15-HYDROXYSTEARATE

Preferably, these cosolvents will be used in combination with ethanol.

According to the invention the silicone agent
5 comprises at least one organopolysiloxane elastomer.

By organopolysiloxane elastomer is meant any chemically crosslinked siloxane polymer which exhibits viscoelastic properties.

By viscoelastic properties is meant the
10 capability of the elastomer to deform up to a certain point, when subjected to mechanical loading, and to regain its original shape following removal of the said loading.

According to one particular embodiment of the
15 invention the organopolysiloxane elastomer is formulated in a vehicle comprising at least one volatile silicone oil.

By a volatile silicone oil is meant any silicone oil capable of evaporating on contact with the
20 skin, the mucosae or the keratin fibres in less than one hour at ambient temperature and atmospheric pressure.

As examples of volatile silicone oils mention may be made, for example, of linear or cyclic polyorganosiloxane oils having in particular 2 to 10 silicon atoms and optionally containing alkyl or alkoxy groups having 1 to 22 carbon atoms. These silicone oils exhibit in particular a viscosity of less than or equal to 6 centistokes ($6 \times 10^{-6} \text{ m}^2/\text{s}$).

The volatile silicone oils include in particular the low molecular weight cyclomethicones and dimethicones or mixtures thereof. In particular the volatile silicone oils are selected from cyclic methyl organopolysiloxanes having ring sizes ranging from 4 to 12, such as octamethylcyclotetrasiloxane and decamethylcyclopentasiloxane. As a volatile silicone oil which can be used in the invention mention may also be made of dodecamethylcyclohexasiloxane, heptamethylhexyltrisiloxane, heptamethyloctyltrisiloxane, hexamethyldisiloxane, octamethyltrisiloxane, decamethyltetrasiloxane, dodecamethylpentasiloxane and mixtures thereof.

As organopolysiloxane elastomers which can be used in the compositions of the invention, mention may be made of those which are described in particular in patents US 4 980 167 and US 4 742 142. The compounds in question may in particular be compounds resulting from addition reactions, i.e. products of hydrosilylation or products of polymerization obtained from the addition

of an organopolysiloxane having unsaturated groups such as vinyl or allyl groups, linked in particular to at least one terminal Si atom, and another silicone compound capable of participating in the addition
5 reaction, such as an organohydropolysiloxane.

Mention may in particular be made of silicone elastomers such as those prepared by crosslinking reaction between polysiloxanes (A) containing $\equiv\text{Si-H}$ groups as defined below, an alpha,omega-diene (B) in
10 the presence of a catalyst and a low molecular weight cyclic or linear polysiloxane (C).

The polysiloxane (A) containing the $\equiv\text{Si-H}$ unit may be represented by compounds of formula $\text{R}^{14}_3\text{SiO}(\text{R}^{15}_2\text{SiO})_a(\text{R}^{16}\text{HSiO})_b\text{SiR}^{14}_3$, denoted here as type A^1 ,
15 and the compounds of formula $\text{HR}^{14}_2\text{SiO}(\text{R}^{15}_2\text{SiO})_c\text{SiR}^{14}_2\text{H}$ or of formula $\text{HR}^{14}_2\text{SiO}(\text{R}^{15}_2\text{SiO})_a(\text{R}^{16}\text{HSiO})_b\text{SiR}^{14}_2\text{H}$, denoted here as type A^2 . In these formulae R^{14} , R^{15} and R^{16} are alkyl groups having one to six carbon atoms, a is an integer varying from 0 to 250, b is an integer varying from 1
20 to 250 and c is an integer varying from 0 to 250. The molar ratio of the compounds, $\text{A}^2:\text{A}^1$, is from 0 to 20, in particular from 0 to 5.

The alpha,omega-diene (B) is a compound of formula $\text{CH}_2=\text{CH}(\text{CH}_2)_d\text{CH}=\text{CH}_2$ in which d is an integer
25 varying from 1 to 20. Representative examples of appropriate alpha,omega-dienes are 1,4-pentadiene, 1,5-hexadiene, 1,6-heptadiene, 1,7-octadiene, 1,8-nona-

diene, 1,9-decadiene, 1,11-dodecadiene, 1,13-tetradecadiene, and 1,19-eicosadiene.

The expression "low molecular weight polysiloxane (C)" encompasses:

- 5 - linear, cyclic or branched volatile methylsiloxanes of low molecular weight,
- linear or cyclic, volatile or non-volatile alkyl- and arylsiloxanes of low molecular weight, and
- linear or cyclic functional siloxanes of low
- 10 molecular weight.


Advantageously the oil (C) is selected from linear or cyclic volatile methylsiloxanes of low molecular weight.

As linear volatile methylsiloxanes mention
15 may be made of hexamethyldisiloxane, octamethyltrisiloxane, decamethyltetrasiloxane, dodecamethylpentasiloxane, tetradecamethylhexasiloxane and hexadecamethylheptasiloxane.

As cyclic volatile methylsiloxanes mention
20 may be made of hexamethylcyclotrisiloxane, octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane and dodecamethylcyclohexasiloxane.

As branched volatile methylsiloxanes mention
may be made in particular of heptamethyl-3-[(trimethyl-
25 silyl)oxy]trisiloxane, hexamethyl-3,3-bis[(trimethylsilyl)oxy]trisiloxane, and pentamethyl[(trimethylsilyl)oxy]cyclotrisiloxane.

Likewise suitable as compounds (C) in the present invention are non-volatile, low molecular weight polysiloxanes of the general formula:



5

in which:

- e is such that the polymers conforming to this formula exhibit a viscosity in the range of approximately 100 to 1000 centistokes (mm²/sec), and is
10 selected in particular from the range from 80 to 375,

- R¹⁷ and R¹⁸ are alkyl radicals having 1 to 20 carbon atoms or an aryl group such as a phenyl group.

Among these polysiloxanes mention may be made in particular of polydimethylsiloxane, polydiethyl-
15 siloxane, polymethylethylsiloxane, polymethylphenylsiloxane and polydiphenylsiloxane.

Functionalized polysiloxanes of low molecular weight may be represented by fluid siloxanes which carry acrylamide, acrylate, amide, amino, carbinol,
20 carboxyl, chloroalkyl, epoxy, glycol, ketal, mercapto, methyl ester, perfluoro and silanol functions.

Examples of elastomers thus obtained are described in particular in patent US 5,654,362.

Preferably, the silicone elastomer used in
25 the compositions of the invention is in particular of ST Elastomer 10[®] from Dow Corning, which is a silicone

elastomer formulated in a decamethylcyclopentasiloxane oil, in the form of a thick, translucent gel.

This type of elastomer is synthesized by a crosslinking reaction similar to that described above; that is, it is prepared by a crosslinking reaction between polysiloxanes (A) containing $\equiv\text{Si-H}$ groups as defined above, an alpha,omega-diene (B) in the presence of a catalyst, and a linear or cyclic polysiloxane of low molecular weight (C), to which vinylsiloxanes (or vinylsilanes) (A') containing $-\text{CH}=\text{CH}_2$ vinyl groups are added.

The reason for this is that it has been demonstrated that the addition of these vinylsiloxanes (or vinylsilanes) blocks the remaining SiH functions which have not reacted ("quenching agent"). The compounds (A') which can be used for preparing the preferred silicone agents according to the invention are of the type described in US application 5,929,164. Examples of such vinylsiloxane or vinylsilane compounds (A') include vinyl-t-butyldimethylsilane, vinyl-diethylmethylsilane, vinyl-ethyl-dimethylsilane, vinyl-triethylsilane, vinyl-trimethylsilane, divinyl-dimethylsilane, divinyl-tetramethyldisilane, vinyl-pentamethyldisiloxane, 1,3-divinyl-tetramethyldisiloxane, a vinyl-trisiloxane of structure $(\text{CH}_3)_3\text{SiOSi}(\text{CH}=\text{CH}_2)(\text{CH}_3)\text{OSi}(\text{CH}_3)_3$, 1,5-divinyl-hexamethyl-trisiloxane, and a divinylsiloxane oligomer having a $(\text{CH}_2=\text{CH})\text{Me}_2\text{SiO}(\text{Me}_2\text{SiO})_8\text{SiMe}_2(\text{CH}=\text{CH}_2)$

structure.

The preferred alpha,omega-diene(B) according to the invention is 1,5-hexadiene.

According to one particular embodiment the
5 silicone agents according to the invention are preferably polysiloxane elastomers which did not contain a hydrophilic group. By a hydrophilic group, according to the invention, is meant, for example, a group of polyoxyalkylene type or a group of glycol
10 type.

The above-defined silicone elastomer may fulfil in particular the function of a thickener in the compositions according to the invention. It may further be involved in stabilizing the said compositions.

15 Likewise suitable as silicone elastomers in accordance with the invention are silicone polymers having an average molecular weight of at least 10 000 (for example ranging from 10 000 to 10 000 000). Examples of silicone polymers include crosslinked
20 siloxane copolymers, for example copolymers of dimethicone or dimethicone derivatives, such as the stearyl-methyl-dimethylsiloxane copolymer (Gransil SR-CYC® from the company Grant Industries), Polysilicone-11® (i.e. a crosslinked silicone elastomer formed by
25 reacting vinyl-terminated silicone and methylhydro-dimethylsiloxane in the presence of cyclomethicone), crosslinked cetearyldimethicone/vinyldimethicone

copolymers (i.e. a cetearyldimethicone copolymer crosslinked with a vinyl dimethyl polysiloxane), a crosslinked dimethicone/phenyl vinyl dimethicone polymer (i.e. a dimethyl polysiloxane copolymer crosslinked with
5 phenyl vinyl dimethyl siloxane), and a crosslinked dimethicone/vinyl dimethicone copolymer (i.e. a dimethyl polysiloxane copolymer crosslinked with vinyl dimethyl siloxane).

Silicone gels of this kind may be obtained
10 commercially in particular from Grant Industries. Examples of such gels include the mixture of cyclomethicone and polysilicone-11 sold for example under the name Gransil GCM5[®], the mixture of cyclotetrasiloxane and polysilicone-11 sold for example under the
15 name Gransil PS-4[®], the mixture of cyclopentasiloxane and polysilicone-11 sold for example under the name Gransil PS-5[®], the mixture of cyclopentasiloxane, dimethicone and polysilicone-11 sold for example under the name Gransil DMCM-5[®], the mixture of cyclotetra-
20 siloxane, dimethicone and polysilicone-11 sold for example under the name Gransil DMCM-4[®], the mixture of polysilicone-11 and isododecane sold for example under the name Gransil IDS[®], and the mixture of cyclo-
methicone, polysilicone-11 and phytosphingosine sold
25 for example under the name Gransil SPH[®]. Examples of gels available from the company General Electric include in particular a crosslinked polymer called

cyclopentasiloxane and dimethicone/vinyldimethicone crosspolymer SFE839®.

Other silicone gels may also be obtained commercially in particular from Shin-Etsu under the following references: KSG-15, KSG-16 and KSG-17, and KSG-21.

Advantageously the amount of silicone agent in a composition of the invention is from 20 to 95% by weight relative to the total weight of the composition, preferably from 20 to 90% by weight.

The amount of silicone agent in a composition of the invention may vary substantially, in particular depending on the viscosity of the desired composition.

Advantageously the amount of organopolysiloxane elastomer in a composition of the invention is from 5 to 80% by weight relative to the total weight of the composition, preferably from 10 to 40% by weight.

As indicated above, the preferred silicone agent is "ST Elastomer 10®" from Dow Corning, a commercial product composed of an organopolysiloxane elastomer present at a concentration of 12% in a decamethylcyclopentasiloxane oil (approximately 85%).

The composition according to the invention may further comprise various other ingredients. The selection of these supplementary ingredients, like that of their respective amounts, is made so as not to do detriment to the expected properties of the

composition. In other words these compounds must not adversely affect the chemical stability of the active principles or their solubility.

According to one advantageous embodiment of
5 the invention the composition further comprises an antioxidant selected from the group consisting of butylated hydroxytoluene (BHT), butylated hydroxy-anisole (BHA), DL-alpha-tocopherol, superoxide
10 as disodium edetate.

According to another advantageous embodiment the composition further comprises an oily additive selected from the group consisting of isopropyl palmitate, dicaprylyl ether, dimethicone or mixtures
15 thereof.

In the compositions of the invention the addition of an oily additive makes it possible to avoid fluffing and to have a light, more substantive residue from the standpoint of the treatment of psoriasis.

20 The composition of the invention may further comprise one or more pharmaceutical excipients suitable for topical application.

By way of examples of pharmaceutical excipients suitable for topical application mention may
25 be made of:

- wetting agents;
- flavour enhancers;

- stabilizers;
- moisture regulators;
- pH regulators;
- osmotic pressure modifiers;
- 5 - emulsifiers;
- UV-A and UV-B filters;
- penetration promoters;
- and synthetic polymers.

As will be appreciated, the person skilled in
10 the art will ensure that any compound or compounds to
be added to these compositions will be selected such
that the advantageous properties intrinsically attached
to the present invention are not, or not substantially,
adversely affected by the intended addition.

15 According to one advantageous embodiment of
the invention the composition is in the form of an
ointment, gel, cream or unguent.

Preferably the compositions of the invention
are in the form of an ointment. For the purposes of the
20 present invention and in accordance with the U.S.
Pharmacopeia (USP) an ointment is a semisolid
preparation intended for external application to the
skin or mucosae. Ointments or unguents are used
topically for numerous applications, for example as
25 barrier creams, antiseptic creams, emollient creams,
etc. Ointments are used for their emollient effect;
they are simple to apply and readily penetrate the

skin.

Advantageously the compositions according to the invention prove, following application, to be exempt from effects of stickiness, greasiness and shine
5 and instead to provide a soft feel. This new type of ointment enhances absorption through the skin, leaves a non-greasy powdery residue and provides ease of application, allowing improvement in the adherence by the patient to his or her treatment. Moreover, one
10 advantageous aspect of this composition is the absence of preservative.

Additionally the inventive compositions show themselves to be particularly effective for preserving satisfactory chemical stability of the active
15 principles which are sensitive to oxidation, to water and to aqueous environments in general. The term "satisfactory chemical stability" applies to a composition which, over a period of at least three months, respectively at ambient temperature and at
20 40°C:

- does not present any substantial modification of its macroscopic appearance,
- has an active principles content of at least 80%, in particular at least 90% and more particularly
25 at least 95% of the initial weight content.

The present invention likewise pertains to the use of a silicone agent comprising at least one

organopolysiloxane elastomer for preparing an anhydrous pharmaceutical composition intended for the treatment of psoriasis, the said composition comprising as active principles vitamin D or a vitamin D derivative and a corticosteroid, the said active principles each being in a solubilized form.

In the abovementioned use the pharmaceutical composition is as defined above.

According to one advantageous embodiment of the invention the composition is prepared cold, in other words at ambient temperature between 20°C and 25°C. The composition is prepared by mixing at least two distinct phases: a phase comprising at least the silicone agent and a phase comprising at least the active principles and the solvent or solvents of the said active principles.

The examples below illustrate the invention; they do not limit it in any way whatsoever.

Example 1: Solubility and stability tests on the active principles

The stability of calcitriol was tested in various solvents, including ethanol 100 and a 75%/25% ethanol 100/cyclomethicone mixture.

a) Stability of calcitriol in ethanol

A 30 ppm solution of calcitriol in absolute ethanol to 100% is prepared in the presence of 0.02% of butylated hydroxytoluene (BHT).

5 The results of an HPLC assay technique against a reference are indicated in table 1 below.

At the starting time (T0) the calcitriol concentration is taken to be 100%.

10 Table 1:

Stability conditions	T 1 week	T 2 weeks	T 3 weeks	T 4 weeks
-18°C	100.9%	100.5%	99.5%	99.5%
+4°C	97.7%	98.6%	98.1%	97.7%
+30°C	/	93.4%	/	93.0%

b) Stability of calcitriol in the (ethanol/cyclopentasiloxane) mixture

15

A 30 ppm solution of calcitriol in absolute ethanol to 100% is prepared in the presence of 0.02% of BHT.

20 The results of an HPLC assay technique against a reference are indicated in table 2 below.

At the starting time (T0) the calcitriol concentration is taken to be 100%.

Table 2:

Stability conditions	T 2 weeks	T 3 weeks	T 4 weeks
-18°C	100.4%	101.3%	99.2%
+4°C	99.2%	99.6%	97.5%
+30°C	93.8%	/	93.3%

5 Example 2: Preparation of a composition of the invention

The process described below is a general process for preparing a silicone ointment comprising a vitamin D derivative and a corticosteroid. The process
10 is carried out at ambient temperature, between 20°C and 25°C.

a) First step: Preparation of the phase comprising the
15 silicone agent (phase A)

The constituents of phase A are weighed out into a beaker: Elastomer ST 10®, silicone oil and oily additive.

20 These constituents are homogenized until a homogeneous gel is obtained.

b) Second step: Preparation of the phase comprising the active principles (phase B)

A stock solution is prepared which comprises
5 a vitamin D derivative in an appropriate solvent and an antioxidant. The solution is stirred until the active dissolves.

The corticosteroid is weighed out and placed
in its solvent. The solution is stirred until the
10 active dissolves.

The two active phases are incorporated into
phase A with stirring. The mixture is homogenized.

When the solvent is the same for both active
principles, the corticosteroid is added to the stock
15 solution of the vitamin D derivative.

Example 3: Example of a pharmaceutical composition of the invention

20

(1) composition

Composition 1	
Ingredients	Amounts in % weight per weight
ISOPROPYL PALMITATE (oily additive)	1

CYCLOPENTASILOXANE (oil)	16
CYCLOMETHICONE 5/ DIMETHICONE CROSSPOLYMER (silicone agent)	74.9347
BUTYLATED HYDROXYTOLUENE (antioxidant)	0.04
CALCITRIOL (active)	0.0003
CLOBETASOL PROPIONATE (active)	0.025
ABSOLUTE ETHANOL (solvent)	8

(2) Physical stability

The physical stability of the compositions is measured by macroscopic and microscopic observation of the composition at ambient temperature, at 4°C and at 40°C after 15 days, 1 month, 2 months and 3 months.

Conclusion:

At ambient temperature the macroscopic observation makes it possible to ensure the physical integrity of the compositions and the microscopic observation makes it possible to verify that there is no recrystallization of the solubilized active principles.

At 4°C the microscopic observation verifies the non-recrystallization of the solubilized active principles.

At 40°C the macroscopic observation verifies
5 the integrity of the final composition.

Characterization of the final composition is completed with a measurement of the flow point. A Haake rheometer of type VT550 is used with a SVDIN measuring spindle. The rheograms are performed at 25°C and at a
10 shear rate of 4 s^{-1} (γ), measuring the shearing stress. By flow point (τ_0 expressed in pascals) is meant the force required (minimum shearing stress) to overcome the van der Waals cohesion forces and bring about the flow. The flow point is taken to be the value found at
15 a shear rate of 4 s^{-1} .

These measurements are carried out at T0 and after 1, 2 and 3 months.

These measurement techniques show that the composition of the invention is stable at least for 1
20 month at 4°C and 40°C.

Specifications at T0

Opalescent colourless flexible ointment

Time→ Stability conditions↓	T 1M	T 2M	T 3M
AT	Complies with specifications	Complies with specifications	Complies with specifications
+4°C	Complies with specifications	Complies with specifications	Complies with specifications
+40°C	Complies with specifications	Complies with specifications	Complies with specifications

(3) Chemical stability of the actives within the composition

5 Stability of calcitriol

The active is assayed by external calibration in HPLC.

Time→	T0	T 15 days	T 1M	T 2M
Stability conditions↓				
AT	102.2%	100.7%	101.7%	103.3%
+40°C		109.8%	111.0%	103.6%

10 Stability of clobetasol 17-propionate

Assay of the active by internal calibration
in HPLC.

30

Time→ Stability conditions↓	T0	T 15 days	T 1M	T 2M
AT	103.2%	101.6%	101.0%	103.0%
+40°C		106.4%	108.6%	111.4%

Example 4: Example of a pharmaceutical composition of the invention

Composition 2	
Ingredients	Amounts in % weight per weight
DICAPRYLYL ETHER (oily additive)	15
BUTYLATED HYDROXYTOLUENE (antioxidant)	0.04
CALCITRIOL (active)	0.0003
CYCLOPENTASILOXANE (oil)	8
CYCLOMETHICONE 5 / DIMETHICONE CROSSPOLYMER (silicone agent)	75.935
CLOBETASOL PROPIONATE (active)	0.025
ABSOLUTE ETHANOL (solvent)	1

The physical stability of the compositions is measured as described above. The conclusions are identical with what was described before.

5 **Example 5: Example of a pharmaceutical composition of the invention**

Composition 3	
Ingredients	Amounts in % weight per weight
DIMETHICONE 200-350cSt	1
CYCLOPENTASILOXANE	12
CYCLOMETHICONE 5/ DIMETHICONE CROSSPOLYMER	qs 100
BUTYLATED HYDROXYTOLUENE	0.04
CALCITRIOL	0.0003
CLOBETASOL PROPIONATE	0.025
ABSOLUTE ETHANOL	8

The physical stability of the compositions is
10 measured as described above. The conclusions are
identical with what was described before.

Example 6: Example of a pharmaceutical composition of the invention

CONSTITUENTS	%
ISOPROPYL PALMITATE	1
CYCLOPENTASILOXANE	12
CYCLOMETHICONE 5/DIMETHICONE CROSS POLYMER	QS 100
BUTYLATED HYDROXYTOLUENE	0.04
CALCITRIOL	0.0003
CLOBETASOL 17-PROPIONATE	0.025
ABSOLUTE ETHANOL	6

5 a) physical stability of the composition

Time→ Stability conditions↓	T 1M	T 2M	T 3M
AT	Complies with specifications	Complies with specifications	Complies with specifications
+4°C	Complies with specifications	Complies with specifications	Complies with specifications
+40°C	Complies with specifications	Complies with specifications	Complies with specifications

(b) Chemical stability of the actives within the composition

Stability of calcitriol

Time→ Stability conditions↓	T0	T 1M	T 2M	T 3M
AT	115.4%	115%	115.2%	119.2%
+40°C		111.9%	119.7%	119.5%

5 *Stability of clobetasol 17-propionate*

Time→ Stability conditions↓	T0	T 1M	T 2M	T 3M
AT	98.0%	99.2%	97.1%	99.6%
+40°C		98.1%	100.2%	98.9%

Example 7: Example of a pharmaceutical composition of the invention

10

CONSTITUENTS	%
N-Methyl-2-pyrrolidone	0.80
CYCLOPENTASILOXANE	9
CYCLOMETHICONE 5/DIMETHICONE CROSS POLYMER	QS 100
BUTYLATED HYDROXYTOLUENE	0.04
CALCITRIOL	0.0003
CLOBETASOL 17-PROPIONATE	0.05
ABSOLUTE ETHANOL	6

a) physical stability of the composition

Time→ Stability conditions↓	T 1M	T 2M
AT	Complies with specifications	Complies with specifications
+4°C	Complies with specifications	Complies with specifications
+40°C	Complies with specifications	Complies with specifications

5 (b) Chemical stability of the actives of the
composition*Stability of calcitriol*

Time→ Stability conditions↓	T0	T 1M	T 2M
AT	104.1%	107.6%	102.9%
+40°C		103.1%	103.3%

Stability of clobetasol 17-propionate

Time→ Stability conditions↓	T0	T 1M	T 2M
AT	98.4%	102.7%	100.4
+40°C		101.0%	100.0

Example 8: Example of a pharmaceutical composition of**the invention**

CONSTITUENTS	%
PEG 400	1.00
CYCLOPENTASILOXANE	9
CYCLOMETHICONE 5/DIMETHICONE CROSS POLYMER	QS 100
BUTYLATED HYDROXYTOLUENE	0.04
CALCITRIOL	0.0003
CLOBETASOL 17-PROPIONATE	0.05
ABSOLUTE ETHANOL	6

a) physical stability of the composition

Time→ Stability conditions↓	T 1M	T 2M
AT	Complies with specifications	Complies with specifications

36

+4°C	Complies with specifications	Complies with specifications
+40°C	Complies with specifications	Complies with specifications

(b) Chemical stability of the actives within the composition

5 Stability of calcitriol

Time→ Stability conditions↓	T0	T 1M	T 2M
AT	106.4%	103.3%	105.2%
+40°C		101%	102.8%

Stability of clobetasol 17-propionate

Time→ Stability conditions↓	T0	T 1M	T 2M
AT	102.8%	98.6%	99.6%
+40°C		97.5%	92.3%

10

Example 9: Study of the release/penetration in vitro on human skin of the active clobetasol 17-propionate contained in 3 different formulations, including one according to the invention

The objective is to quantify the skin penetration of the formulated active in different formulations *in vitro* on human skin after 16 hours of application.

5

Formulations tested:

- Temovate® emollient cream containing 0.05% (w/w) of clobetasol 17-propionate
- Temovate® cream containing 0.05% (w/w) of clobetasol
- 10 17-propionate
- Composition according to the invention of formula A below:

Ingredients	Amounts in % weight per weight
ISOPROPYL PALMITATE (oily additive)	1
CYCLOPENTASILOXANE (oil)	16
CYCLOMETHICONE 5/ DIMETHICONE CROSSPOLYMER (silicone agent)	74.9347
BUTYLATED HYDROXYTOLUENE (antioxidant)	0.04
CALCITRIOL (active)	0.0003

CLOBETASOL PROPIONATE (active)	0.025
ABSOLUTE ETHANOL (solvent)	8

The Temovate® creams are sold by the company Glaxo Smith Kline.

- 5 **Experimental conditions:** The percutaneous absorption is evaluated by means of diffusion cells consisting of 2 compartments separated by human skin. The formulations were applied without occlusion for an application time of 16 hours. The formulations were
- 10 applied at a rate of 10 mg of formulation per cm² (i.e. 10 micrograms of clobetasol 17-propionate). Throughout the study, the dermis is in contact with a receiving liquid which is not renewed as a function of time (static mode). The experiments were conducted with
- 15 3 samples of skin originating from 3 different donors. At the end of the application period, the surface excess is removed and the distribution of the clobetasol 17-propionate is quantified in the different compartments of the skin and in the receiving liquid.
- 20 The concentrations of clobetasol 17-propionate were quantified using a HPLC/MS/MS method which is conventionally known to the skilled person. (LQ: 1 ng.ml⁻¹).

The results are expressed as a % of the applied dose (mean +/- standard deviation) and are set out in the table below.

Formulation		Total amount having penetrated
Emollient Temovate cream	Mean	5.00
	SEM	1.34
Temovate cream	Mean	8.43
	SEM	0.79
Composition A	Mean	9.96
	SEM	1.36

5

The results show that the amount of clobetasol having penetrated with the composition according to the invention is equivalent to that of the Temovate cream.

CLAIMS

1. Anhydrous pharmaceutical composition intended for the treatment of psoriasis, characterized in that
5 it comprises a silicone agent comprising at least one organopolysiloxane elastomer, a compound A selected from vitamin D or a vitamin D derivative and a compound B selected from a corticosteroid, the said compounds A and B each being in a solubilized form in the said
10 composition.
2. Pharmaceutical composition according to Claim 1, characterized in that the difference in optimum pH stability of the compound A and the optimum pH stability of the compound B is at least 1.
- 15 3. Composition according to either of Claims 1 and 2, characterized in that the vitamin D derivative is selected from the group consisting of calcipotriol, calcitriol or 1,25-dihydroxyvitamin D₃, doxercalciferol, secalcitol, maxacalcitol, seocalcitol, tacalcitol,
20 paricalcitol, falecalcitriol, 1 α ,24S-dihydroxyvitamin D₂, 1(S),3(R)-dihydroxy-20(R)-[[(3-(2-hydroxy-2-propyl)phenyl)methoxy)methyl]-9,10-secopregna-5(Z),7(E),10(19)-triene and mixtures thereof.
4. Composition according to Claim 3,
25 characterized in that the vitamin D derivative is calcitriol.
5. Composition according to any one of Claims 1

to 4, characterized in that the corticosteroid is selected from the group consisting of betamethasone, clobetasol, clobetasone, desoxymethasone, diflucortolone, diflorasone, fluocinonide,

5 flumethasone, fluocinolone, fluticasone, fluprednidene, halcinonide, hydrocortisone, momethasone, triamcinolone and their pharmaceutically acceptable esters and acetonides and mixtures thereof.

6. Composition according to Claim 5,
10 characterized in that the esters or acetonides are selected from the group consisting of 17-valerate, 17-propionate, 17,21-dipropionate, acetonide, acetonide-21-N-benzoyl-2-methyl- β -alaninate, acetonide-21-(3,3-dimethylbutyrate) and 17-butyrate.

15 7. Composition according to either of Claims 5 and 6, characterized in that the corticosteroid is clobetasol 17-propionate.

8. Composition according to any one of Claims 1 to 7, characterized in that the compounds A and B are
20 solubilized in the same solvent or in two or more solvents.

9. Composition according to any one of Claims 1 to 8, characterized in that it is intended for topical application.

25 10. Composition according to any one of Claims 1 to 9, characterized in that it has a water content of less than or equal to 5% by weight relative to the

total weight of the composition, in particular less than or equal to 3%, and especially zero.

11. Composition according to Claim 8, characterized in that the solvent is selected from the
5 group consisting of:

- aliphatic alcohols having 1 to 6 carbon atoms such as ethanol, isopropanol, butanol and mixtures thereof;

- oils such as caprylic and capric
10 triglycerides, cetearyl isononanoate, vegetable oils such as sweet almond oil, sesame oil, wheatgerm oil, olive oil and mixtures thereof; and mixtures thereof.

12. Composition according to Claim 11,
15 characterized in that the solvent is ethanol.

13. Composition according to any one of Claims 1 to 12, characterized in that the organopolysiloxane elastomer is formulated in at least one volatile silicone oil selected from linear or cyclic
20 polyorganosiloxane oils having 2 to 10 silicon atoms and optionally containing alkyl or alkoxy groups of 1 to 22 carbon atoms.

14. Composition according to any one of Claims 1 to 13, characterized in that the amount of silicone
25 agent is from 20 to 90% by weight relative to the total weight of the composition, preferably from 30 to 80% by weight.

15. Composition according to any one of Claims 1 to 14, characterized in that the amount of organopolysiloxane elastomer is from 20 to 90% by weight relative to the total weight of the composition, preferably from 30 to 80% by weight.

16. Composition according to any one of Claims 1 to 15, characterized in that the amount of vitamin D or vitamin D derivative in solubilized form is from 0.00001 to 5% by weight relative to the total weight of the composition.

17. Composition according to any one of Claims 1 to 16, characterized in that the amount of vitamin D or vitamin D derivative in solubilized form is from 0.0001 to 3% by weight.

18. Composition according to any one of Claims 1 to 17, characterized in that the amount of vitamin D or vitamin D derivative in solubilized form is from 0.0003 to 1% by weight.

19. Composition according to any one of Claims 1 to 18, characterized in that the amount of corticosteroid in solubilized form is from 0.00005 to 3% by weight relative to the total weight of the composition.

20. Composition according to any one of Claims 1 to 19, characterized in that the amount of corticosteroid in solubilized form is from 0.0001 to 1% by weight.

21. Composition according to any one of Claims 1 to 20, characterized in that the amount of corticosteroid in solubilized form is from 0.001 to 0.1% by weight.
- 5 22. Composition according to any one of Claims 8 to 21, characterized in that the amount of solvent is from 1 to 50% by weight relative to the total weight of the composition, preferably from 2 to 40% by weight and more particularly from 5 to 20% by weight.
- 10 23. Composition according to any one of Claims 1 to 22, characterized in that it further comprises an antioxidant selected from the group consisting of butylated hydroxytoluene (BHT), butylated hydroxy-anisole (BHA), DL-alpha-tocopherol, superoxide
- 15 dismutase, ubiquinol or certain chelating agents.
24. Composition according to any one of Claims 1 to 23, characterized in that it further comprises an oily additive selected from the group consisting of isopropyl palmitate, dicaprylyl ether, dimethicone or
- 20 mixtures thereof.
25. Composition according to any one of Claims 1 to 24, characterized in that it comprises one or more pharmaceutical excipients suitable for topical application.
- 25 26. Composition according to any one of Claims 1 to 25, characterized in that it is in the form of an ointment, gel, cream or unguent.

27. Use of a silicone agent comprising at least one organopolysiloxane elastomer for preparing an anhydrous pharmaceutical composition intended for the treatment of psoriasis, the said composition comprising
5 as active principles vitamin D or a vitamin D derivative and a corticosteroid, the said active principles each being in a solubilized form.
28. Use according to Claim 27, wherein the composition is as defined in any one of Claims 1 to 26.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2005/007974

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/573 A61K31/59 A61K31/592 A61K31/593 A61K47/08
 A61K47/10 A61K47/14 A61K47/24 A61P17/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 755 675 A (OREAL) 29 January 1997 (1997-01-29) page 2, line 28 - line 32 page 2, line 44 - page 3, line 42 page 5, line 11 - line 23 page 5, line 40 - line 42 page 6, line 21	1-28
Y	EP 0 998 943 A (PANIN GIORGIO) 10 May 2000 (2000-05-10) page 2, line 40 - page 3, line 12 page 3, exemple ----- -/-	1-28



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

21 October 2005

Date of mailing of the international search report

03/11/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Albrecht, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2005/007974

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4 738 956 A (WORTZMAN MITCHELL S ET AL) 19 April 1988 (1988-04-19) column 2, line 5 - line 39 column 2, line 54 - line 67 column 3, line 9 - line 17 column 3, line 27 - line 61 column 4, line 22 - line 32 examples 1,2	1-28
Y	WO 01/87344 A (SEIGFRIED BERND G ; PIOTROWIAK RALF (DE); MIKA PHARMA GES FUER DIE ENT) 22 November 2001 (2001-11-22) page 2, line 6 - line 10 page 6, line 8 - page 7, line 30 page 10, line 26 - line 35 page 12, lines 15,24 page 13, line 7 - line 12 page 14, line 1 - line 5 examples 8,9 page 26, line 10 - line 17 page 27, line 2 - line 9	1-28
Y	EP 0 679 392 A (LAFON LABOR) 2 November 1995 (1995-11-02) page 2, line 31 - line 37 page 2, line 56 - page 3, line 51 page 4, line 14 - line 22 examples 1-12,23-26	1-28
Y	FR 2 738 745 A (CIRD GALDERMA) 21 March 1997 (1997-03-21) page 1, line 9 - line 15 page 5, line 20 - page 6, line 25 page 7, line 6 - line 19 page 8, line 8 - line 14 page 8, line 31 - page 9, line 2 page 13, line 29 - page 14, line 4	1-28
Y	WO 00/64450 A (HOEY GERT ; DIDRIKSEN ERIK (DK); LEO PHARM PROD LTD (DK)) 2 November 2000 (2000-11-02) cited in the application page 1, line 12 - line 24 page 2, line 1 - line 10 page 3, line 12 - page 9, line 24 page 11, line 3 - page 12, line 9 page 15, line 9 - line 17 examples 1,2	1-28
A	US 4 308 264 A (CONWAY NANCY M ET AL) 29 December 1981 (1981-12-29) column 2, line 42 - line 50	1-28

-/--

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2005/007974

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>ALBERG U ET AL: "Investigation on the long-term stability of corticosteroids in modified water containing hydrophilic ointment"</p> <p>PHARMACEUTICAL AND PHARMACOLOGICAL LETTERS,</p> <p>vol. 8, no. 2, April 1998 (1998-04), pages 53-56, XP009042369</p> <p>ISSN: 0939-9488</p> <p>* page 53, chapter "Introduction" *</p> <p>-----</p>	1-28

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2005/007974

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0755675	A	29-01-1997	AU 679663 B2	03-07-1997
			AU 5943096 A	13-02-1997
			CA 2182226 A1	29-01-1997
			DE 69600065 D1	23-10-1997
			DE 69600065 T2	08-01-1998
			ES 2109832 T3	16-01-1998
			FR 2737118 A1	31-01-1997
			JP 2965510 B2	18-10-1999
			JP 9040548 A	10-02-1997
			US 6136332 A	24-10-2000
EP 0998943	A	10-05-2000	AT 232742 T	15-03-2003
			DE 69905438 D1	27-03-2003
			DE 69905438 T2	20-11-2003
			ES 2190175 T3	16-07-2003
			IT MI982075 A1	27-03-2000
			US 6280752 B1	28-08-2001
US 4738956	A	19-04-1988	NONE	
WO 0187344	A	22-11-2001	AU 7383901 A	26-11-2001
			DE 10024413 A1	06-12-2001
			EP 1282446 A1	12-02-2003
			JP 2003533491 T	11-11-2003
			US 2003170194 A1	11-09-2003
EP 0679392	A	02-11-1995	AT 210430 T	15-12-2001
			AU 680731 B2	07-08-1997
			AU 1767595 A	16-11-1995
			CA 2148112 A1	30-10-1995
			DE 69524470 D1	24-01-2002
			DE 69524470 T2	23-05-2002
			DK 679392 T3	08-04-2002
			ES 2169746 T3	16-07-2002
			FR 2719220 A1	03-11-1995
			HK 1008658 A1	26-04-2002
			HU 75251 A2	28-05-1997
			JP 2740465 B2	15-04-1998
			JP 8059456 A	05-03-1996
			KR 233770 B1	01-12-1999
			NZ 272014 A	26-05-1997
			PT 679392 T	31-05-2002
			TW 448050 B	01-08-2001
			ZA 9503392 A	28-10-1996
FR 2738745	A	21-03-1997	AT 218349 T	15-06-2002
			AU 687687 B2	26-02-1998
			AU 6991296 A	01-04-1997
			BR 9606648 A	16-09-1997
			CA 2204437 A1	20-03-1997
			DE 69621580 D1	11-07-2002
			DE 69621580 T2	13-03-2003
			DK 788361 T3	15-07-2002
			EP 0788361 A1	13-08-1997
			ES 2181908 T3	01-03-2003
			WO 9709987 A1	20-03-1997
			JP 2898100 B2	31-05-1999
			JP 10503533 T	31-03-1998

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2005/007974

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
FR 2738745	A		NZ 318430 A	29-09-2000
			PT 788361 T	29-11-2002
			US 6759396 B1	06-07-2004
WO 0064450	A	02-11-2000	AU 774600 B2	01-07-2004
			AU 2278300 A	10-11-2000
			BG 106030 A	31-05-2002
			BR 0009956 A	08-01-2002
			CA 2370565 A1	02-11-2000
			CN 1351499 A	29-05-2002
			CZ 20013739 A3	12-06-2002
			EP 1178808 A1	13-02-2002
			HK 1045650 A1	08-04-2005
			HR 20010779 A1	31-12-2002
			HU 0200879 A2	28-08-2002
			JP 2002542293 T	10-12-2002
			MX PA01010676 A	20-08-2003
			NO 20015175 A	23-10-2001
			NZ 515142 A	30-01-2004
			PL 351387 A1	07-04-2003
			RU 2238734 C2	27-10-2004
			SK 15182001 A3	04-06-2002
			US 6753013 B1	22-06-2004
US 4308264	A	29-12-1981	AU 549765 B2	13-02-1986
			AU 7961382 A	05-08-1982
			CA 1174605 A1	18-09-1984
			CH 651208 A5	13-09-1985
			DE 3202622 A1	09-09-1982
			FR 2498450 A1	30-07-1982
			GB 2091556 A	04-08-1982
			IL 64798 A	30-11-1984
			JP 1378149 C	08-05-1987
			JP 57144218 A	06-09-1982
			JP 61044845 B	04-10-1986
			NZ 199472 A	31-05-1984